Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.

Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kühne T, Jürgens H, van den Berg H, Böhling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M, EURAMOS-1 investigators

Open source

DOI: 10.1200/jco.2014.60.0734
Published: 2015 Jul 10
Container: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco.2014.60.0734,
  title = {Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.},
  author = {Bielack SS and Smeland S and Whelan JS and Marina N and Jovic G and Hook JM and Krailo MD and Gebhardt M and Pápai Z and Meyer J and Nadel H and Randall RL and Deffenbaugh C and Nagarajan R and Brennan B and Letson GD and Teot LA and Goorin A and Baumhoer D and Kager L and Werner M and Lau CC and Sundby Hall K and Gelderblom H and Meyers P and Gorlick R and Windhager R and Helmke K and Eriksson M and Hoogerbrugge PM and Schomberg P and Tunn PU and Kühne T and Jürgens H and van den Berg H and Böhling T and Picton S and Renard M and Reichardt P and Gerss J and Butterfass-Bahloul T and Morris C and Hogendoorn PC and Seddon B and Calaminus G and Michelagnoli M and Dhooge C and Sydes MR and Bernstein M and EURAMOS-1 investigators},
  year = {2015},
  journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  doi = {10.1200/jco.2014.60.0734},
  url = {https://doi.org/10.1200/jco.2014.60.0734}
}

RIS

TY  - JOUR
TI  - Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.
AU  - Bielack SS
AU  - Smeland S
AU  - Whelan JS
AU  - Marina N
AU  - Jovic G
AU  - Hook JM
AU  - Krailo MD
AU  - Gebhardt M
AU  - Pápai Z
AU  - Meyer J
AU  - Nadel H
AU  - Randall RL
AU  - Deffenbaugh C
AU  - Nagarajan R
AU  - Brennan B
AU  - Letson GD
AU  - Teot LA
AU  - Goorin A
AU  - Baumhoer D
AU  - Kager L
AU  - Werner M
AU  - Lau CC
AU  - Sundby Hall K
AU  - Gelderblom H
AU  - Meyers P
AU  - Gorlick R
AU  - Windhager R
AU  - Helmke K
AU  - Eriksson M
AU  - Hoogerbrugge PM
AU  - Schomberg P
AU  - Tunn PU
AU  - Kühne T
AU  - Jürgens H
AU  - van den Berg H
AU  - Böhling T
AU  - Picton S
AU  - Renard M
AU  - Reichardt P
AU  - Gerss J
AU  - Butterfass-Bahloul T
AU  - Morris C
AU  - Hogendoorn PC
AU  - Seddon B
AU  - Calaminus G
AU  - Michelagnoli M
AU  - Dhooge C
AU  - Sydes MR
AU  - Bernstein M
AU  - EURAMOS-1 investigators
PY  - 2015
JO  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DO  - 10.1200/jco.2014.60.0734
UR  - https://doi.org/10.1200/jco.2014.60.0734
ER  -

APA

SS, B., S, S., JS, W., N, M., G, J., JM, H., MD, K., M, G., Z, P., J, M., H, N., RL, R., C, D., R, N., B, B., GD, L., LA, T., A, G., D, B., L, K., M, W., CC, L., K, S. H., H, G., P, M., R, G., R, W., K, H., M, E., PM, H., P, S., PU, T., T, K., H, J., H, V. D. B., T, B., S, P., M, R., P, R., J, G., T, B., C, M., PC, H., B, S., G, C., M, M., C, D., MR, S., M, B., & investigators, E. (2015). Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco.2014.60.0734

Source records

pubmed · retrieved 2026-09-27T09:51:09.354Z
europe-pmc · retrieved 2026-09-27T09:51:09.353Z